


Quick Update:

- Membership: 601 members
- Very successful ASNO-COGNO Scientific Meeting 2016



COGNO

COOPERATIVE TRIALS GROUP
FOR NEURO-ONCOLOGY

Member Newsletter

Issue 23

Spring 2016

Inside this issue:

Chairman's Message	1
ASNO-COGNO Scientific Meeting 2016 report	2-3
Getting to Know COGNO's MC Members: Prof Meera Agar	4
Study & Trial Updates	4-6
New Concepts/ Trials in Development	6-7
Membership Update	7
COGNO Team Updates	7
More photos from ASNO-COGNO Scientific Meeting 2016	8-10
Reminders and Additional Information	10

Message from our Chair



Dear COGNO members,

This newsletter comes at a change of seasons, the annual change in the sporting landscape, a sense that the year is quickly coming to an end, and a disbelief that it will soon be 2017.

The COGNO/ASNO ASM seems a distant memory but much of this newsletter focuses on our wonderful meeting. The Organising Committee worked assiduously and collaboratively for over 12 months and it would seem almost unfair to single anyone out. But Mustafa and Zarnie did an exceptional job with the scientific program and Zarnie overcame almost insurmountable problems to bring our "Outreach Fellows" to Sydney. The social program was terrific, the quality of the scientific presentations first class and I really felt we gave appropriate prominence to this being an ASNO meeting first and a COGNO meeting second.

For me there a number of highlights: first and foremost, Mitch Bergers' description of how he practices as a doctor: an intensely personal description of his values. Secondly, Mustafa gave a tour de force presentation on immunotherapy, that would have held its own at any meeting anywhere in the world. Third was our "Outreach Program" that allowed a number of junior consultants in the field to come from their countries to attend a meeting that I'm sure was beyond their resources. But my ultimate highlight was the presentation of the Hubert Stuerzl award with his widow Wendy and two children in attendance. I don't think any of them realised the regard with which we held Hubert.

The ASM gave us an opportunity to hold our traditional "open SAC" ably chaired by Liz Hovey and with the great advantage of international luminaries involved in the discussions.

Finally, I pay special tribute to Jenny and Yi, who managed the entire ASM circus without a solitary issue coming across my desk for resolution.

As for the remainder of the newsletter, we have an interesting insight into what makes Meera tick and there is considerable detail about the two COGNO studies that are up and running: VERTU and ACED.

All the best for the remainder of the year and I hope each and every one of you enjoys time away in December and January.

Mark Rosenthal
Group Chair

13TH ASIAN SOCIETY FOR NEURO-ONCOLOGY (ASNO) MEETING / 9TH COGNO ANNUAL SCIENTIFIC MEETING

Neuro-Oncology: is the landscape changing?

11th - 14th September 2016, Sheraton on the Park, Sydney, Australia

COGNO is proud to have hosted the very successful ASNO-COGNO Scientific Meeting 2016, and to have had the honour of welcoming delegates from the ASNO member countries. ASNO-COGNO 2016 was the largest neuro-oncology meeting ever held in Australia, attracting delegates from 20 countries. The scientific program, headlined by key International and Australian experts in the field, provided a forum for clinicians, researchers, allied health, care coordinators, nurses, carers, consumers and many others to network, hear about brain cancer research in many countries and learn from the very best. Congratulations and thanks to the Organising Committee and sub-committees on a fantastic meeting and outstanding program.

Organising Committee: Prof Mark Rosenthal (COGNO Chair and 2016 ASNO President), Drs Elizabeth Hovey and Cecelia Gzell (Co-Convenors), Drs Zarnie Lwin and Mustafa Khasraw (Scientific Program Co-Leads), Dr Jonathon Parkinson (Consumer Forum Lead), Ms Jenny Chow (COGNO Executive Officer)

Sub-Committees:

Scientific Program: Dr Mustafa Khasraw, Dr Zarnie Lwin, Dr Jonathon Parkinson

SRS Workshop: Dr Cecelia Gzell, Dr Matthew Foote, Dr Ben Jonker, Dr Claire Phillips, Ms Yi Feng

Glioma Master Class: Prof Mark Rosenthal, Dr Elizabeth Hovey

Social: Dr Zarnie Lwin, Dr Adrian Lee, Ms Sally McCowatt

Sponsorship: Dr Elizabeth Hovey, Dr Cecelia Gzell, Ms Jenny Chow, Ms Alexandra Davidson

Visit <http://asnocogno2016.org.au/> for more information on our International and Australian speakers, official meeting abstracts and program.

Congratulations to our award and grant recipients:

- **MSD Hubert Stuerzl Memorial Educational Award** - Dr James Dimou
- **COGNO Outreach Education Preceptorship** - Dr Poly Bunpa (Cambodia), Dr Phyu Phyu Theint and Dr Aye Aye Myint (Myanmar), Dr Hoang Nguyen Hoai An (Vietnam).
- **COGNO-Abbvie Most Outstanding Oral Presentation** - A/Prof Kerrie McDonald for her presentation on *"Repurposing Ibudilast in combination with temozolomide for Glioblastoma"*
- **COGNO-Cure Brain Cancer Foundation Most Outstanding Poster Presentation** - Dr Satoshi Suehiro for his abstract *"5-aminolevulinic acid-mediated sonodynamic therapy (5-ala-sdt) using high intensity focused ultrasound (hifu) enhanced the antitumor activity by inducing necrosis and apoptosis of malignant gliomas"*
- **COGNO-Bristol-Myers Squibb Young Investigator Award** - Yi Chieh Lim for his poster abstract *"A brain tumour organotypic culture platform to bridge the gap of lead compound discovery and drug validation"*. Yi Chieh's report appears on page 3.



L-R Ms Josie Downey (MSD), Mrs Wendy Stuerzl, Dr James Dimou & Prof Mark Rosenthal



L-R Dr Zarnie Lwin, Dr Poly Bunpa, Dr Phyu Phyu Theint, Dr Aye Aye Myint & Prof Mark Rosenthal



L-R Prof Mark Rosenthal with Wendy, India and Luis Stuerzl, Ms Josie Downey, Dr Liz Hovey & Dr Zarnie Lwin



A/Prof Kerrie McDonald

13TH ASIAN SOCIETY FOR NEURO-ONCOLOGY (ASNO) MEETING / 9TH COGNO ANNUAL SCIENTIFIC MEETING

Neuro-Oncology: is the landscape changing?

11th - 14th September 2016, Sheraton on the Park, Sydney, Australia

COGNO-BRISTOL-MYERS SQUIBB YOUNG INVESTIGATOR AWARD REPORT



Dr Cecelia Gzell & Dr Yi Chieh Lim

Over the course of my scientific career, I have come to realise glioblastoma is a devastating disease that is highly resistant to current standard of care. Radio- and alkylating-based drug therapies are ineffective and tumour recurrence is almost inevitable. New therapies are urgently needed on a clinical level to help improve patient survival. I recognise the pressing need for better treatment modalities and have begun developing an accurate method to identify potential compounds that can be used for clinical trial testing. Current technology often employs the use of tumour cells grown in artificial environment to evaluate drug efficacy. Unfortunately, this approach lacks the cellular microenvironment to reflect the disease origin and can lead to inconsistent discovery. While orthotopic animal model is the accepted standard to validate drug efficacy, the approach is slow and costly. The brain organotypic culture slice which is presently used in our laboratory is designed to simulate the actual tumour behaviour by cultivating GBM patient specimens directly on polycarbonate membrane. My research goal is to integrate this assay to an imaging-based high throughput system for a robust, cost-efficient and accurate drug screen. The approach will greatly reduce the attrition rate of candidate compounds which can be potentially tested in the clinic.

We thank all our supporters and sponsors of the ASNO-COGNO Scientific Meeting 2016. The Scientific Program was developed independent of sponsor involvement.

Diamond Sponsor



Platinum Sponsor



Silver & Barista Sponsor



Bronze Sponsor



SRS Workshop Sponsors



Other Meeting Supporters



CABARET FOR COGNO FUNDRAISER

COGNO's first public fundraising event, Cabaret for COGNO, was held during ASNO-COGNO 2016. We thank everyone who made this a success: [the fabulous artists who donated their time](#), [those who donated the wonderful raffle prizes](#), [our tireless volunteers](#) and of course everyone who attended. Well done to event producer, Dr Liz Hovey!



Cabaret for COGNO performers Valvere at BTAA table with Susan Pitt



Dr Zarnie Lwin, Prof Ryo Nishikawa (ASNO Secretary General) & Prof Mark Rosenthal

(more photos on page 8)

GETTING TO KNOW COGNO'S MANAGEMENT COMMITTEE MEMBERS



Professor Meera Agar is on the COGNO Management Committee and Scientific Advisory Committee. Meera works as a Palliative Medicine Physician at Liverpool Hospital, NSW and is the Professor of Palliative Medicine, University of Technology Sydney. Her doctoral studies explored delirium in advanced cancer.

How did you become involved in COGNO?

I have been involved in COGNO since its inception, having had a clinical interest in improving care for people with brain tumours and their families. I was fortunate to work in the same clinical service with Dr Eng-Siew Koh and Dr Liz Hovey and learnt a great deal about neuro-oncology through collaborative care of brain tumour patients. My research interest is in the area of supportive needs of people who have brain impacts from their advanced illness, and their families.

Why are you still a COGNO member?

COGNO is truly transdisciplinary, and the research questions it aims to tackle really matter. I am also humbled by the input of our consumer investigators who have truly enhanced the outcomes and impact of the research COGNO has achieved. The COGNO community is supportive and constructive. Tackling research questions using clinical trials in palliative care is often tough, with significant challenges in trial design, outcome choice and feasibility; COGNO provides mentorship and robust scientific input to make this possible.

Why did you become a palliative medicine specialist?

Palliative Medicine allows me to support people and their families to live well, despite the presence of an advanced progressive illness.

It allows clinical practice which is not limited by hospital boundaries, provides many complex clinical challenges and is supported by an interdisciplinary team. A paper by Karen Steinhauser in JAMA in 2000 really made me think about the value people place on mental capacity at the end of life, and this led me to developing a research program in this area. This has included people with brain tumours, delirium in other cancer settings and advanced dementia.

What is a typical workday for you?

As most working mothers will attest, the day begins getting all bodies out of the house in one piece, with all the required lunch boxes, musical instruments and school books. My working week is part clinical, which includes outpatient based clinic at Liverpool, supporting participants who are on clinical trials and home visits. My academic role involves higher degree supervision, postgraduate teaching, grant writing and trying to finish those papers which never seem to write themselves. I am also involved in broader education/training and advocacy, through Palliative Medicine Training (RACP) and am the President Elect for the ANZ Society of Palliative Medicine.

How do you stay motivated to continue your role?

Supporting people to feel as well as possible, and be able to be in the place of care of their choice is the main motivator. I see our role as facilitator - understanding what the person needs and wants, and then using our skills and resources to try and make those things happen. The investment from family carers, without which care for people with cancer in Australia would fall down, is also inspiring. What we provide is such a small piece in comparison to their contribution. I think the other important thing is working as a team, and supporting each other especially when facing difficult situations.

STUDY & TRIAL UPDATES

CATNON (EORTC 26053-22054): Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma

Recruitment for the CATNON study closed on 17 Sep 2015 with 751 patients randomised internationally (1407 registered), and 82 randomised in Australia (191 registered); this represents approximately 11% of total trial accrual and is a great contribution to the global effort.

(continues on page 5)

CATNON (EORTC 26053-22054): Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma



Professor Martin van den Bent (study coordinator—EORTC) presented the CATNON trial at the ASCO Conference on 3 June 2016 and discussed the latest safety data. Professor Anna Nowak presented these results of the interim analysis at ASNO-COGNO 2016.

Pharmacy close outs are underway at the sites that no longer have patients on treatment.

Joe Levitt is available to provide any information that you may require and can be reached by emailing any questions or requests to catnon@ctc.usyd.edu.au.

CATNON PI, Dr Anna Nowak, presenting at ASNO-COGNO 2016

ACED (COGNO14/02): Phase II randomised placebo-controlled, double blind, multisite study of acetazolamide versus placebo for management of cerebral oedema in recurrent and/or progressive HGG requiring treatment with dexamethasone.

The ACED study aims to recruit 84 patients across 12 sites. While preparing for start of recruitment some important changes were identified to the protocol. Therefore a protocol amendment was submitted to the Ethics Committee on 15 February 2016. This has now been approved centrally and V2.0 dated 8 February 2016, has been sent to sites for local submissions.

Meanwhile the first two sites have been activated - Liverpool Hospital (NSW) and Royal Brisbane and Women's Hospital (QLD). Liverpool Hospital has recruited the first patient for the study. St Vincent's Hospital will have their site initiation on the 13/Oct/2016 and will be activated soon after. The study team continues working diligently to prepare all study documents, systems and procedures to facilitate an efficient conduct of the trial.

We are in the process of site selection for the remaining sites. Please email aced@ctc.usyd.edu.au if you have any queries.

ACED - PARTICIPATING SITE STATUS						
No	Site name	State	Principal Investigator	Site status	Site activation	# Patients randomised
1	Liverpool Hospital	NSW	Eng-Siew Koh	Active	24/Jun/2016	1
2	Royal Brisbane and Women's Hospital	QLD	Zarnie Lwin	Active	30/Sep/2016	0
3	St Vincent's Hospital, Melbourne	VIC	Anthony Dowling	Initiation scheduled 13/Oct/2016	Pending	-
4	Epworth Healthcare	VIC	Ross Jennens	Pending RGO approval	Pending	-
5	Princess Alexandra Hospital	QLD	Katharine Cuff	SSA in progress	Pending	-
6	Sir Charles Gairdner Hospital	WA	Anna Nowak	Local HREC in progress	Pending	-
7	Prince of Wales Hospital	NSW	Elizabeth Hovey	SSA in progress	Pending	-
8	Flinders Medical Centre	SA	Ganessan Kichenadasse	SSA in progress	Pending	-
Total recruitment						1

VERTU (COGNO 14/01): Veliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma. A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT).

The VERTU Trial has now been open to recruitment for nearly 12 months. To date, we have registered 97 patients and randomised 26. Sites are actively looking for potential participants and new patients are being registered every week. As expected, there are quite some screen failures due to MGMT methylation and decline in performance status prior to randomisation. To ensure recruitment rates remain on target, all participating sites are requested to continue actively searching for patients that may be suitable to join the trial.

An Investigator teleconference was held in June 2016 to discuss recruitment strategies, best practices and shared experiences so far on the VERTU trial.

Just a reminder that all trial documentation can be accessed via the NHMRC CTC Trial Web pages (<http://ctc.usyd.edu.au>) for those working on the trial. If you do not have access to this trial specific webpage and require an account to be set up, please let us know.

The VERTU Trial Coordinator is more than happy to provide any information that you may require on this study. Please email vertu@ctc.usyd.edu.au if you have any queries.

VERTU - PARTICIPATING SITE STATUS							
No	Site name	State	Principal Investigator	Site status	Site activation	# Patients registered	# Patients enrolled
1	Canberra Hospital	ACT	Ganes Pranavan	Not active	TBC	-	-
2	Royal North Shore Hospital	NSW	Helen Wheeler	Active	09-Nov-15	29	5
3	Chris O'Brien Lifehouse	NSW	John Simes	Active	26-Nov-15	10	4
4	Liverpool Hospital	NSW	Eng-Siew Koh	Active	21-Jan-16	7	1
5	Gosford Hospital	NSW	Matthew Wong	Active	7-Jun-16	2	4
6	Royal Melbourne Hospital	VIC	Mark Rosenthal	Active	28-Oct-15	3	1
7	University Hospital Geelong	VIC	David Ashley	Active	21-Jan-16	7	2
8	Epworth Healthcare	VIC	Ross Jennens	Active	14-Dec-15	8	0
9	Monash Medical Centre	VIC	Ronnie Freilich	Active	11-Feb-16	1	0
10	Royal Brisbane and Women's Hospital	QLD	Zarnie Lwin	Active	09-Nov-15	15	6
11	Princess Alexandra Hospital	QLD	Matthew Foote	Active	5-Jul-16	5	1
12	Royal Adelaide Hospital	SA	Nimit Singhal	Active	24-Mar-16	5	1
13	Sir Charles Gairdner Hospital	WA	Anna Nowak	Not active	TBC	-	-
14	Royal Hobart Hospital	TAS	Rosemary Harrup	Active	02-Dec-15	6	1
15	Launceston General Hospital	TAS	Stan Gauden	Not active	TBC	-	-
Total recruitment						97	26

NEW CONCEPTS/TRIALS IN DEVELOPMENT

COGNO held an open Scientific Advisory Committee (SAC) meeting during ASNO-COGNO 2016 on Monday 12 September. Along with 14 SAC members and 5 staff from the Clinical Trials Centre/COGNO, the attendees included 8 international guests comprising a panel of world leading experts across the Neuro-Oncology craft groups, as well as 35 attendees from the COGNO general membership and the 3 newest members of our Consumer Advisory Panel.

A very full agenda included discussion of four new concepts, updates on all ongoing and planned COGNO trials, discussion of opportunities for COGNO to engage with GCCTI (Genomic Cancer Clinical Trials Initiative), and reports from the international attendees regarding opportunities for international collaboration. The opportunity to obtain feedback from not only the COGNO SAC but also the international contingent was an additional bonus for our new concept proposers, and highlighted the impressive standard of COGNO's development program on the world stage.

(continues on page 7)

NEW CONCEPTS/TRIALS IN DEVELOPMENT



Open SAC Meeting

DO YOU HAVE A NEW TRIAL CONCEPT? COGNO is always looking to develop new trials - from inception through to full protocol development and managing feasibility and operational issues. We aim to help progress and support development of important clinical trial questions. If you would like to propose a concept or have an amazing idea for a COGNO trial, please contact us on cogno@ctc.usyd.edu.au or call Michelle Parry (Associate Oncology Program Manager - Development) on 02 9562 5016. Michelle and the team can assist you to develop and progress your idea or assist you with completion of the Trial Concept Outline form available at www.cogno.org.au (on the home page under 'Ideas and Concepts'). The next SAC meeting will be held on Thursday 8 December 2016, with concept outlines due by Friday 18 November 2016.

The COGNO team has been busy assisting in the preparation of four new concepts presented at the September SAC meeting, and is now awaiting the outcome of two grant applications for NHMRC/Cancer Australia/Cancer Council funding, with outcomes due to be released between now and December.

MEMBERSHIP UPDATE

COGNO now has 601 members! Help us expand our Group's expertise and networking capacity. If you know someone who would like to join, you can refer prospective members to our online membership application on our website (www.cogno.org.au) or office (cogno@ctc.usyd.edu.au).

COGNO TEAM UPDATE

We farewell Jaclyn Verghis (ACED Trial Coordinator) and wish her well for a safe delivery of her first child. We thank Jaclyn for all her hard work on the ACED Trial and getting it up and running before her maternity leave.



We welcome Tara Flores to the COGNO trials team as the new ACED Trial Coordinator. Tara has a bachelor's degree in applied science from the University of Sydney. Prior to joining CTC, she worked at Eli Lilly Australia for 6 years starting as a central clinical operations assistant and then as a clinical development technical associate working many priorities such as study start up and coordination of investigator initiated trial proposals.

Some of you may have already worked with Tara, as she initially joined the CTC as an ethics coordinator, which involved initiating start-up activities for new studies as well as closing out sites. Outside the office, Tara is a choir member and enjoys playing volleyball.



Congratulations to Prof John Simes, recipient of the 2016 NSW Premier's Award for Outstanding Cancer Researcher of the Year. John was recognised for enabling over 80,000 people to access new and emerging cancer treatments (<https://www.cancerinstitute.org.au/about-us/events/premiers-research-awards>).

COGNO is extremely lucky to have had the benefit of John's knowledge and expertise through his involvement on the COGNO Management Committee, Scientific Advisory Committee, Operations Executive and a number of its trial management committees. John is also a founding member of COGNO.

More photos from ASNO-COGNO Scientific Meeting 2016



John burning up the dance floor with Susan Pitt and Robyn Leonard during the ASNO-COGNO 2016 Conference Dinner



Prof Donald Berry



SRS Workshop subcommittee members and international speakers Dr Claire Phillips, A/Prof Matthew Foote, A/Prof Arjun Sahgal, Prof Giuseppe Minniti, Dr Ben Jonker, Dr Cecelia Gzell & Dr Tim Solberg



Glioma Master Class subcommittee members and speakers Prof Mitch Berger, Prof Anna Nowak, Prof Mark Rosenthal, Prof Susan Chang & Dr Liz Hovey



Prof Roger Stupp



Prof Rakesh Jalali



Dr Mustafa Khasraw



Dr Anna Barker



More photos from ASNO-COGNO Scientific Meeting 2016

A very Aussie welcome to our international and local guests

MANAGEMENT COMMITTEE

- Prof Mark Rosenthal (Chair)
- Prof John Simes (Deputy Chair)
- Dr Liz Hovey (Treasurer)
- Dr Eng-Siew Koh (Secretary)
- Prof Meera Agar
- Ms Marcia Fleet
- Dr Cecelia Gzell
- A/Prof Georgia Halkett
- Prof Terry Johns
- Ms Robyn Leonard

SCIENTIFIC ADVISORY COMMITTEE

- Dr Liz Hovey (Chair)
- Dr Eng-Siew Koh (Deputy Chair)
- Prof Meera Agar
- Ms Liz Barnes
- A/Prof Kate Drummond
- A/Prof Matthew Foote
- Dr Lindy Jeffree
- Prof Terry Johns
- Ms Marina Kastelan
- Dr Danette Langbecker
- Ms Robyn Leonard
- A/Prof Kerrie McDonald
- Prof Anna Nowak
- Dr Michelle Parry
- Prof Mark Rosenthal
- Dr Gail Ryan
- Prof John Simes
- Dr Helen Wheeler

OPERATIONS EXECUTIVE COMMITTEE

- Prof Mark Rosenthal (Chair)
- Prof John Simes (Deputy Chair)
- Ms Liz Barnes
- Ms Jenny Chow
- Mrs Merryn Hall
- Dr Liz Hovey
- Dr Mustafa Khasraw
- Dr Eng-Siew Koh
- Dr Michelle Parry

COGNO Coordinating Centre
 NHMRC Clinical Trials Centre
 Locked Bag 77
 Camperdown NSW 1450
 T: +61 2 9562 5000
 F: +61 2 9562 5094
 E: cogno@ctc.usyd.edu.au



Dr Zarnie Lwin greeting delegates at the Welcome Reception



Below clockwise: Asst Adj Prof Mary Lovely, Prof Paul Mischel, Prof Al Yung & Prof Gregory Riggins



More photos from ASNO-COGNO Scientific Meeting 2016



L-R Dr Stephen Yau, Dr Jonathon Parkinson & Prof Tim Cloughesy

ASNO Country Updates below clockwise: A/Prof Sith Sathornsumtee (Thailand), Dr Tiara Aninditha (Indonesia), Dr Juliette Batara (Philippines) & Dr Lye-Mun Tho (Malaysia)



More photos from ASNO-COGNO 2016 are available on <https://www.dropbox.com/sh/9nvjcv5es2p31zs/AADvoLWtPLpn2uXWV5N6rEjSa?dl=0> until 19 December 2016

REMINDERS/ADDITIONAL INFORMATION

- 15-17 November 2016 - COSA's 43rd ASM/ANZBCTG's 38th ASM, Gold Coast Convention and Exhibition Centre, Australia <http://cosa2016.org/>
- 17-20 November 2016 - SNO, Fairmont Scottsdale Princess, Scottsdale, USA <http://www.soc-neuro-onc.org/>
- 23 November 2016 - NHMRC 5th Annual Symposium on Research Translation 'Embedding research into health care: building a culture of quality', Melbourne Convention and Exhibition Centre, Australia <http://www.nhmrc2016.com/>
- 24 November 2016 - ACTA 2016 Summit, Melbourne Convention and Exhibition Centre, Australia <http://www.clinicaltrialsalliance.org.au/>
- The latest issue of the annual IBTA Brain Tumour magazine is available on <https://issuu.com/ibta-org/docs/ibta-2016>



COGNO CONTACTS

Michelle Parry
COGNO Development Program Manager
(Mon-Fri)
E: michelle.parry@ctc.usyd.edu.au
T: (02) 9562 5016

Merryn Hall
COGNO Operations Program Manager
(Mon, Tue, Wed)
E: merryn.hall@ctc.usyd.edu.au
T: (02) 9562 5023

Martijn Oostendorp
VERTU Trial Coordinator
(Mon-Fri)
E: vertu@ctc.usyd.edu.au
T: (02) 9562 5372

Tara Flores
ACED Trial Coordinator
(Mon - Thu)
E: aced@ctc.usyd.edu.au
T: 02 9562 5398

Joe Levitt
CATNON Trial Coordinator
(Mon-Thurs)
E: catnon@ctc.usyd.edu.au
T: 02 9562 5391

Diana Winter
CABARET Trial Coordinator
(Tues, Thu, Fri)
E: cabaret@ctc.usyd.edu.au
T: 02 9562 5393

Mustafa Khasraw
CTC Clinical Lead for COGNO
E: mustafa.khasraw@ctc.usyd.edu.au

Jenny Chow
Executive Officer
(Mon, Tues, Wed, Fri)
E: cognoeo@ctc.usyd.edu.au
T: (02) 9562 5389

Yi Feng
Admin Assistant
(Mon, Thu, Fri)
E: yi.feng@ctc.usyd.edu.au
T: (02) 8036 5238

Mythily Mariasegaram
BCBA Project Coordinator
(Mon, Tue)
E: bcba@bcba.org.au
T: (02) 8036 5244